Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valproic acid + dexamethasone (Barbara Ann Karmanos Cancer Institute)
- Development stage
- Unknown
- Lead developer
- Barbara Ann Karmanos Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valproic acid + dexamethasone is a combination regimen investigated by the Barbara Ann Karmanos Cancer Institute for the induction of folate receptor alpha (FRα) as a diagnostic and surveillance biomarker. Valproic acid, a small molecule histone deacetylase (HDAC) inhibitor, and dexamethasone, a synthetic glucocorticoid receptor agonist, are used together to synergistically upregulate the expression of FRα in ovarian cancer cells. This induction is intended to increase the shedding of the receptor into the serum, allowing for more sensitive detection and monitoring of ovarian carcinoma and adnexal masses through laboratory biomarker analysis. The approach is being evaluated in a Phase 1 pilot study to determine if this pharmacological induction can improve the clinical utility of serum folate receptor levels in diagnosing and tracking disease recurrence.
- Other names
- VPA + DEXvalproate + dexamethasone
02
Targets
GR (Glucocorticoid receptor)FOLR1 (FRα)GSK3 (Glycogen synthase kinase 3 beta)Class I and Class IIa histone deacetylases (HDACs)
Beyond the preview
Go deeper on valproic acid + dexamethasone (Barbara Ann Karmanos Cancer Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valproic acid + dexamethasone (Barbara Ann Karmanos Cancer Institute).